Roche Holding AG Akt 1.04% CHF232.83B ...

In a shocking twist that could turn your dream getaway into a nightmare, Airbnb has fired off a stark warning to ...

In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...

The increasing prevalence of kidney failure and end-stage renal disease, along with a growing incidence of risk factors like diabetes, hypertension, and aging, is driving the demand for artificial ...